FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Yorke Justin W			2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106			3. Date of Earliest Transaction (Month/Day/Year) 12/03/2021						r (give title belo	w)	Other (specify	pelow)	
(Stree HANOVER, MD 21076	et)	4. If	f Amendment,	Date Origi	nal F	Filed(Month	/Day/Ye	ear)	_X_ Form fil	ual or Joint/O ed by One Report and by More than	rting Person	Check Applica	ble Line)
(City) (State	e) (Z	Lip)	T	able I - Nor	ı-De	rivative S	Securit	ties Acqu	ired, Dispe	osed of, or I	Beneficially	Owned	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)		Day/Year) Exec	Deemed ution Date, if nth/Day/Year)	Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)		d of (D)			Following		7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	Amount	or (D)	Price				(I) (Instr. 4)	
Common Stock	12/03/20	021		S		5,500	D	\$ 4.8362 (1)	538,617	7		I	By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC
Common Stock 12/06/2021		021		S		4,200	D	\$ 4.7104 (2)	534,411	7		I	By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC
Common Stock									9,323			D	LLC
Reminder: Report on a separat		Гable II - Deriv	vative Securit	ies Acquire	Person the	sons wh tained ir form dis	o responding this splays	form ar a curre Beneficia	e not requently valid	ction of inf iired to res OMB cont	pond unle	ess	1474 (9-02)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Mon Derivative Security	Exe ath/Day/Year) any	. Deemed ecution Date, if	Code (Instr. 8)	5.	6. I and (Mo	Date Exerc Expirationth/Day/	isable on Date	7. T Am Und Sec	Citle and ount of derlying urities str. 3 and		9. Number Derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Owners Form of Derivat Security Direct (or Indir	Beneficial Ownership (Instr. 4)

	Code	V (A)	Exercisable	Expiration Date	Title	Amount or Number of Shares			
--	------	-------	-------------	--------------------	-------	--	--	--	--

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Yorke Justin W C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076	X					

Signatures

s/ Justin W. Yorke by Michael B. Kirwan, as Attorney-in-Fact	12/07/2021	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$4.8001 to \$5.01, inclusive. The Reporting (1) Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$4.5601 to \$4.80, inclusive. The Reporting (2) Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.